About: Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals
Creator	Finzi, Andrés Medjahed, Halima Richard, Jonathan Anand, Sai Kaufmann, Daniel Beaudoin-Bussières, Guillaume Bégin, Philippe Gasser, Romain Gokool, Laurie Goyette, Guillaume Laumaea, Annemarie Lewin, Antoine Martel-Laferrière, Valérie Morrisseau, Chantal Perreault, Josée Prévost, Tremblay,
Source	BioRxiv
abstract	In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for potential transfusion to COVID-19 patients. The therapy has been deemed safe and several clinical trials assessing its efficacy are ongoing. While it remains to be formally proven, the presence of neutralizing antibodies is thought to play a positive role in the efficacy of this treatment. Indeed, neutralizing titers of ≥1:160 have been recommended in some convalescent plasma trials for inclusion. Here we performed repeated analyses at one-month interval on 31 convalescent individuals to evaluate how the humoral responses against the SARS-CoV-2 Spike, including neutralization, evolve over time. We observed that receptor-binding domain (RBD)-specific IgG slightly decreased between six and ten weeks after symptoms onset but RBD-specific IgM decreased much more abruptly. Similarly, we observed a significant decrease in the capacity of convalescent plasma to neutralize pseudoparticles bearing SARS-CoV-2 S wild-type or its D614G variant. If neutralization activity proves to be an important factor in the clinical efficacy of convalescent plasma transfer, our results suggest that plasma from convalescent donors should be recovered rapidly after symptoms resolution.
has issue date	2020-07-09(xsd:dateTime)
bibo:doi	10.1101/2020.07.09.194639
has license	biorxiv
sha1sum (hex)	79ce2380f14bdb096dba4ec433e6e851303b02b8
schema:url	https://doi.org/10.1101/2020.07.09.194639
resource representing a document's title	Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals
schema:publication	bioRxiv
resource representing a document's body	covid:79ce2380f14bdb096dba4ec433e6e851303b02b8#body_text
is schema:about of	named entity 'Word count' named entity 'convalescent' named entity 'Word count' named entity 'humoral responses' named entity 'convalescent plasma' named entity 'SARS-CoV-2' named entity 'convalescent plasma' named entity 'convalescent plasma' named entity 'IgM' named entity 'convalescent plasma' named entity 'RBD' named entity 'infection' named entity 'luciferase' named entity 'SARS-CoV-2' named entity 'Statistical significance' named entity 'RBD' named entity 'glycoprotein' named entity 'Convalescent plasma therapy' named entity 'convalescent plasma' named entity 'potency' named entity 'SARS-CoV-2' named entity 'convalescent plasma' named entity 'infectivity' named entity 'ACE2' named entity 'SARS-CoV-2' named entity 'rhesus macaques' named entity 'infectivity' named entity 'SARS-CoV' named entity 'convalescent plasma' named entity 'convalescent plasma' named entity 'IgM' named entity 'mutation' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'influenza H1N1' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'convalescent plasma' named entity 'conformation' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'plasma' named entity 'infectivity' named entity 'IgG' named entity 'IgM' named entity 'SARS-CoV-2' named entity 'plasma' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'Reverse Transcriptase' named entity 'correlation' named entity 'plasma' named entity 'RBD' named entity 'IgG antibodies' named entity 'antibodies' named entity 'pandemics' named entity 'infectivity' named entity 'RBD' named entity 'COVID' named entity 'IgM' named entity 'glycoprotein' named entity 'Statistical significance' named entity 'plasma' named entity 'IgM' named entity 'MERS' named entity 'clinical outcomes' named entity '293T'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software